ID
17651
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part: Moisturizers and Sunscreens
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (2)
- 1/8/16 1/8/16 -
- 27/9/16 27/9/16 -
Subido en
27 de septiembre de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Similar models
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0038818 (UMLS CUI [2])
C0038818 (UMLS CUI [2])
C0808070 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0808070 (UMLS CUI [2,2])
C0808070 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0808070 (UMLS CUI [2,2])
C0806020 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0806020 (UMLS CUI [2,2])
C0806020 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0806020 (UMLS CUI [2,2])